Literature DB >> 16111597

Organ sparing by conformal avoidance intensity-modulated radiation therapy for anal cancer: dosimetric evaluation of coverage of pelvis and inguinal/femoral nodes.

Yi-Jen Chen1, An Liu, Peter T Tsai, Nayana L Vora, Richard D Pezner, Timothy E Schultheiss, Jeffrey Y C Wong.   

Abstract

PURPOSE: To describe a novel and straightforward conformal avoidance intensity-modulated radiation therapy (IMRT) technique for coverage of pelvis and inguinal/femoral nodes and to compare the dosimetry of the new method with that of other traditional methods of radiation treatment. METHODS AND MATERIALS: Data of 2 patients with anal cancer were used as example cases to illustrate details and advantages of conformal avoidance IMRT technique. Conventional photons with enface electrons design was created first, thereby providing "outermost boundaries" defined as planning target volume (PTV) for subsequent conformal avoidance IMRT design. Organs at risk (OARs), including femoral head and neck and external genitalia, were contoured as conformal avoidance structures. A step-and-shoot inverse IMRT planning was subsequently generated. For dosimetric comparison, a recently published technique by modified segmental boost was also generated. These treatment techniques were evaluated by dose-volume histogram (DVH) of PTV and OARs. Dose profiles at four different depths from each treatment planning were generated for comparison.
RESULTS: The DVH of PTV showed that coverage of the PTV was comparable among three treatment techniques. Percent volume of PTV receiving more than 90% prescription dose was in the range 94-98% for the three treatment techniques, and all had only 0-2% of PTV receiving more than 110% of prescription dose. The DVH of OARs confirmed that both femoral head and neck and external genitalia could be spared well by conformal avoidance IMRT as compared with the other two techniques. Although greater inhomogeneity of dose distribution within the PTV was noted by conformal avoidance IMRT technique, as shown by dose profiles at four different depths, the maximum doses at different depths were less than 115%, which was comparable to those planned by modified segmental boost technique. Planning by photons and enface electrons technique, however, showed a greater dose variation up to 134% of the prescription dose at 1.5 cm depth along photon-electron match-line.
CONCLUSIONS: To cover pelvis and inguinal/femoral nodes, conformal avoidance IMRT is technically simple to simulate, plan, and execute. Dosimetric study has demonstrated that it achieves comparable PTV coverage compared with other approaches while at the same time significantly sparing the surrounding OARs.

Entities:  

Mesh:

Year:  2005        PMID: 16111597     DOI: 10.1016/j.ijrobp.2005.05.052

Source DB:  PubMed          Journal:  Int J Radiat Oncol Biol Phys        ISSN: 0360-3016            Impact factor:   7.038


  23 in total

1.  Intensity-Modulated Radiation Therapy vs. 3D Conformal Radiation Therapy for Squamous Cell Carcinoma of the Anal Canal.

Authors:  Michael D Chuong; Jessica M Freilich; Sarah E Hoffe; William Fulp; Jill M Weber; Khaldoun Almhanna; William Dinwoodie; Nikhil Rao; Kenneth L Meredith; Ravi Shridhar
Journal:  Gastrointest Cancer Res       Date:  2013-03

Review 2.  Management of locally advanced anal canal carcinoma with intensity-modulated radiotherapy and concurrent chemotherapy.

Authors:  Guillaume Klausner; Eivind Blais; Raphaël Jumeau; Julian Biau; Mailys de Meric de Bellefon; Mahmut Ozsahin; Thomas Zilli; Raymond Miralbell; Juliette Thariat; Idriss Troussier
Journal:  Med Oncol       Date:  2018-08-20       Impact factor: 3.064

Review 3.  Update on treatment advances in combined-modality therapy for anal and rectal carcinomas.

Authors:  Jeffrey Meyer; Glen Balch; Christopher Willett; Brian Czito
Journal:  Curr Oncol Rep       Date:  2011-06       Impact factor: 5.075

4.  Toxicity and survival of anal cancer patients treated with intensity-modulated radiation therapy.

Authors:  A Ghareeb; K Paramasevon; P Mokool; H van der Voet; M Jha
Journal:  Ann R Coll Surg Engl       Date:  2018-11-28       Impact factor: 1.891

5.  Volumetric intensity-modulated arc therapy vs. 3-dimensional conformal radiotherapy for primary chemoradiotherapy of anal carcinoma: Effects on treatment-related side effects and survival.

Authors:  Hanne Elisabeth Weber; Leif Hendrik Dröge; Steffen Hennies; Markus Karl Herrmann; Jochen Gaedcke; Hendrik Andreas Wolff
Journal:  Strahlenther Onkol       Date:  2015-06-08       Impact factor: 3.621

6.  Elective clinical target volumes for conformal therapy in anorectal cancer: a radiation therapy oncology group consensus panel contouring atlas.

Authors:  Robert J Myerson; Michael C Garofalo; Issam El Naqa; Ross A Abrams; Aditya Apte; Walter R Bosch; Prajnan Das; Leonard L Gunderson; Theodore S Hong; J J John Kim; Christopher G Willett; Lisa A Kachnic
Journal:  Int J Radiat Oncol Biol Phys       Date:  2008-12-29       Impact factor: 7.038

Review 7.  Squamous-cell carcinoma of the anus: progress in radiotherapy treatment.

Authors:  Rob Glynne-Jones; David Tan; Robert Hughes; Peter Hoskin
Journal:  Nat Rev Clin Oncol       Date:  2016-01-27       Impact factor: 66.675

Review 8.  Chronic adverse events and quality of life after radiochemotherapy in anal cancer patients. A single institution experience and review of the literature.

Authors:  K Fakhrian; T Sauer; A Dinkel; S Klemm; T Schuster; M Molls; H Geinitz
Journal:  Strahlenther Onkol       Date:  2013-05-02       Impact factor: 3.621

9.  Impact of intensity modulated radiation therapy on survival in anal cancer.

Authors:  Jaymin Jhaveri; Lael Rayfield; Yuan Liu; Mudit Chowdhary; Sibo Tian; Richard J Cassidy; Theresa Gillespie; Pretesh R Patel; Jerome C Landry; Kirtesh R Patel
Journal:  J Gastrointest Oncol       Date:  2018-08

10.  A fast radiotherapy paradigm for anal cancer with volumetric modulated arc therapy (VMAT).

Authors:  Florian Stieler; Dirk Wolff; Frank Lohr; Volker Steil; Yasser Abo-Madyan; Friedlieb Lorenz; Frederik Wenz; Sabine Mai
Journal:  Radiat Oncol       Date:  2009-10-25       Impact factor: 3.481

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.